Jocelyn Lee
A5021379845- Molecular Biology Techniques and Applications
- DNA and Nucleic Acid Chemistry
- Gene expression and cancer classification
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Prostate Cancer Treatment and Research
- RNA modifications and cancer
- Genetics, Bioinformatics, and Biomedical Research
- Biomedical and Engineering Education
- Ubiquitin and proteasome pathways
- Cancer, Lipids, and Metabolism
- Bioinformatics and Genomic Networks
- Genomics and Chromatin Dynamics
- Biotechnology and Related Fields
- Genomic variations and chromosomal abnormalities
- Nutrition and Health in Aging
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- PI3K/AKT/mTOR signaling in cancer
- Innovative Microfluidic and Catalytic Techniques Innovation
- PARP inhibition in cancer therapy
- Colorectal Cancer Treatments and Studies
- Extracellular vesicles in disease
- Advanced Breast Cancer Therapies
American Association For Cancer Research
2020-2024
Ontario Genomics
2024
National Cancer Institute
2014-2017
National Institutes of Health
2017
Uniformed Services University of the Health Sciences
2015-2016
Stanford University
2016
Public Health Agency of Canada
2015
GeneTrace Systems (United States)
2007
Abstract International cancer registries make real-world genomic and clinical data available, but their joint analysis remains a challenge. AACR Project GENIE, an international registry collecting from 19 centers, makes >130,000 patients publicly available through the cBioPortal for Cancer Genomics (https://genie.cbioportal.org). For 25,000 patients, additional longitudinal data, including treatment outcome are being collected by GENIE Biopharma Collaborative using PRISSMM curation...
AKT inhibitors have promising activity in AKT1 E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis clinical outcomes patients with matched (n = 153) and AKT1-wild-type 302) cancer. AKT1-mutant cases had similar adjusted overall survival (OS) compared controls (median OS, 24.1 vs....
The RAS family of small GTPases represents the most commonly activated oncogenes in human cancers. To better understand prevalence somatic mutations and compendium genes that are coaltered RAS-mutant tumors, we analyzed targeted next-generation sequencing data 607,863 from 66,372 tumors 51 cancer types AACR Project GENIE Registry. Bayesian hierarchical models were implemented to estimate cancer-specific non-RAS mutations, evaluate co-occurrence mutual exclusivity, model effects tumor...
ABSTRACT Vaccinia E3 protein has the biochemical capacity of binding to double-stranded RNA (dsRNA). The best characterized biological functions include its host range function, suppression cytokine expression, and inhibition interferon (IFN)-induced antiviral activity. Currently, role dsRNA in is not clear. To further understand mechanism functions, we performed alanine scanning entire domain examine link between functions. Of 115 mutants examined, 20 were defective binding. Although...
Abstract Patients with non-small cell lung cancer (NSCLC) who have distant metastases a poor prognosis. To determine which genomic factors of the primary tumor are associated metastasis, we analyzed data from 759 patients originally diagnosed stage I–III NSCLC as part AACR Project GENIE Biopharma Collaborative consortium. We found that TP53 mutations were significantly development new metastases. also more prevalent in history smoking, suggesting these may be at increased risk for...
Abstract The RAS family of small GTPases represents the most commonly activated oncogenes and mutations in KRAS, NRAS HRAS are found approximately one third all human cancers. To better understand prevalence somatic compendium genes that have RAS-dependent co-mutation frequencies an unbiased pan-cancer manner, we analyzed targeted next-generation sequence data from AACR Project GENIE Registry (GENIE version 6.1-public). Our analyses utilized 644,757 64,217 tumors 97 cancer types. A Bayesian...
Abstract Introduction: Mutations in the RAS family of proto-oncogenes are frequently found NSCLC, with KRAS being most prevalent mutated isoform. Of mutations, common is G12C, representing ~40% mutations and occurring ~13% all lung adenocarcinoma cases. The objective this study to describe clinicopathological molecular characteristics, treatment patterns, outcomes patients G12C-mutated metastatic NSCLC using AACR Project GENIE database. Methods: An observational retrospective adult...
Abstract Introduction: Prostate cancer (CaP) affects 1 in 7 men throughout their life time. One of the major risk factors for development CaP is race/ethnicity. African American (AA) have significantly higher incidence and mortality from compared to Caucasian (CA). Our laboratory others recently described that driver genes, including ERG PTEN, different frequencies AA versus CA CaP. In recent years progress has been made evaluating expression role long noncoding RNAs (lncRNAs) prostate...
There is currently limited literature assessing the real-world treatment patterns and clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) homologous recombination repair (HRR) mutations. Medical charts were abstracted for mCRPC ≥ 1 12 HRR somatic gene alterations treated at US oncology centers participating in American Association Cancer Research Project Genomics Evidence Neoplasia Information Exchange. Treatment assessed from initiation first-line or...
<p>List of AACR Project GENIE Consortium Members</p>
Abstract Introduction: In comparison to other ethnicities African American men have the highest incidence and mortality rates of prostate cancer (CaP). Recent reports on ethnic differences ERG oncogenic activation, most common CaP genomic alteration, provide new insights into based stratification in context increasingly diverse patient populations United States. This rapidly advancing knowledge has potential stratify by typing a given population that may eventually lead targeted treatments....
You have accessJournal of UrologyProstate Cancer: Basic Research V1 Apr 2015MP66-06 OPTIMIZATION OF NANOSTRING PLATFORM FOR EVALUATION PROSTATE CANCER BIOMARKERS AND THERAPEUTIC TARGETS IN FFPE SPECIMENS Wusheng Yan, Denise Young, Yingjie Song, Yongmei Chen, Shilpa Katta, Lakshmi Ravindranath, Jocelyn Lee, Alagarsamy Srinivasan, Jennifer Cullen, Jacob Kagan, Sudhir Srivastava, Albert Dobi, Inger Rosner, David G. McLeod, Isabell A. Sesterhenn, Shiv and Gyorgy Petrovics YanWusheng Yan More...
Abstract Introduction: Identification of prognostic indicators disease progression is one the highest priorities in prostate cancer (CaP) research. The majority CaP tissue specimens available for biomarker discovery and validation are formalin fixed paraffin embedded (FFPE) specimens. RNA quality these tissues traditional gene expression analysis approaches not adequate, especially cases with long term- follow up necessary marker studies. We systematically evaluated optimized NanoString...
41 Background: KRAS mutation accounts for ~37% of colorectal cancer (CRC), with G12C occurring in ~3% CRC tumors. is associated poorer prognosis terms real-world progression-free survival (rwPFS) and overall (OS) compared to other mutations wild-type. As mutated metastatic (mCRC) recognized as a discrete potentially druggable target, there need further describe this patient population. This retrospective cohort study provides clinicopathological molecular characteristics, treatment patterns,...
Abstract Background: Limited information is available about real-world treatment patterns and survival among patients with metastatic breast cancer (mBC) BRCA1/2 mutations. mutations, which are involved in the repair of DNA double-strand breaks, rare. Since 2018, PARP inhibitors (olaparib talazoparib) have been approved for germline BRCA-mutated HER2-negative locally advanced and/or mBC. Methods: This retrospective chart review study included adults diagnosed mBC ≥1 oncogenic somatic...
<div>Abstract<p>The RAS family of small GTPases represents the most commonly activated oncogenes in human cancers. To better understand prevalence somatic mutations and compendium genes that are coaltered RAS-mutant tumors, we analyzed targeted next-generation sequencing data 607,863 from 66,372 tumors 51 cancer types AACR Project GENIE Registry. Bayesian hierarchical models were implemented to estimate cancer-specific non-RAS mutations, evaluate co-occurrence mutual exclusivity,...
Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers
Supplementary Data from Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers